AR070071A1 - Derivados de n- fenil - imidazo (1,2-alfa) piridin -2- carboxamidas, su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de n- fenil - imidazo (1,2-alfa) piridin -2- carboxamidas, su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR070071A1 AR070071A1 ARP080105776A ARP080105776A AR070071A1 AR 070071 A1 AR070071 A1 AR 070071A1 AR P080105776 A ARP080105776 A AR P080105776A AR P080105776 A ARP080105776 A AR P080105776A AR 070071 A1 AR070071 A1 AR 070071A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- phenyl
- imidazo
- hydrogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composicion farmacéutica y usos para tratar enfermedades que involucran los receptores nucleares Nurr-1. Reivindicacion 1: Compuestos de formula (1), en la que: X representa un grupo fenilo sustituido con un ciano, un alcoxi C1-6carbonilo, un alcoxi C1-6 sustituido con uno o varios halogenos o alquilo C1-6 sustituido con uno o varios halogenos, estando el fenilo opcionalmente sustituido una segunda vez con un halogeno; R1 representa un átomo de hidrogeno, un halogeno, un grupo alcoxi C1-6, alquilo C1-6, un grupo NRaRb; pudiendo estar los grupos alquilo y alcoxi sustituidos opcionalmente con uno o varios halogeno, hidroxi, amino o grupo alcoxi C1-6, R2 representa uno de los siguientes grupos: un átomo de hidrogeno, un grupo alquilo C1-6 opcionalmente sustituido con uno o varios grupos elegidos independientemente uno de otros entre un hidroxi, halogeno, amino, un grupo NRaRb, un grupo alcoxi C1-6, un grupo fenilo, un grupo alcoxi C1-6 opcionalmente sustituido con uno o varios grupos elegidos independientemente uno de otros entre hidroxi, halogeno, amino, grupo NRaRb, un grupo alquenilo C2-6, alquinilo C2-6; -CO-R5, -CO-NR6R7, -CO-O-R8, -NR9-CO-R10, -NR11R12, -N=CH-NRaRb, un átomo de halogeno, un grupo ciano, nitro, hidroxiiminoalquilo, alcoxiiminoalquilo, un grupo alquiltio C1-6, alquil C1-6sulfinilo, alquil C1-6sulfonilo, (alquil C1-6)3sililetinilo, -SO2-NR9R10, fenilo opcionalmente sustituido con uno o varios grupos elegidos independientemente uno de otros entre los átomos o grupos siguientes: halogeno, alcoxi C1-6, ciano, NRaRb, -CO-R5, -CO-NR6R7, -CO-O-R8, un grupo alquilo C1-6 opcionalmente sustituido con uno o varios hidroxi o NRaRb, R3 representa un átomo de hidrogeno, un grupo alquilo C1-6, alcoxi C1-6 o un átomo de halogeno, R4 representa un átomo de hidrogeno, un grupo alquilo C1-4, alcoxi C1-4 o un átomo de fluor, R5 representa un átomo de hidrogeno, un grupo fenilo o alquilo C1-6, R6 y R7, idénticos o diferentes, representan un átomo de hidrogeno o un grupo alquilo C1-6 o forman con el átomo de nitrogeno un ciclo de 4 a 7 eslabones que incluye opcionalmente otro heteroátomo elegido entre N, O o S; R8 representa un grupo alquilo C1-6, R9 y R10, idénticos o diferentes, representan un átomo de hidrogeno o un grupo alquilo C1-6; R11 y R12 idénticos o diferentes, representan un átomo de hidrogeno o un grupo alquilo C1-6 o forman con el átomo de nitrogeno un ciclo de 4 a 7 eslabones que incluye opcionalmente otro heteroátomo elegido entre N, O o S; Ra y Rb representan, independientemente uno de otros, un átomo de hidrogeno, un grupo alquilo C1-6 o forman con el átomo de nitrogeno un ciclo de 4 a 7 eslabones, con la excepcion de los compuestos en los que R1 representa un grupo metilo o R2 representa un átomo de cloro o R3 representa un grupo metilo, en el estado de base o de sal de adicion de un ácido, con la excepcion de los compuestos: N-(3-cloro-4-cianofenil)-imidazo[1,2-a}piridina-2-carboxamida, 3-({[imidazo[1,2-a]piridina-2-il]carbonil}amino)benzoato de metilo, 2-({[imidazo[1,2-a]piridina-2-il]carbonil}amino)benzoato de metilo, N-[2-(difluorometoxi)fenil]-imidazo[1,2-a]piridina-2-carboxamida, N-[3-(trifluorometoxi)fenil]-6-(dimetilamino)imidazo[1,2-a]piridina-2-carboxamida, N-[3-(difluorometoxi)fenil]-6-(dimetilamino)imidazo{1,2-a]piridina-2-carboxamida, y N-[3-(trifluorometil)fenil]-6-(dimetilamino)imidazo[1,2-a]piridina-2-carboxamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800002A FR2925900B1 (fr) | 2008-01-02 | 2008-01-02 | DERIVES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070071A1 true AR070071A1 (es) | 2010-03-10 |
Family
ID=39691313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105776A AR070071A1 (es) | 2008-01-02 | 2008-12-30 | Derivados de n- fenil - imidazo (1,2-alfa) piridin -2- carboxamidas, su preparacion y su aplicacion en terapeutica |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20100317685A1 (es) |
| EP (1) | EP2225241B1 (es) |
| JP (1) | JP2011508758A (es) |
| KR (1) | KR20100099245A (es) |
| CN (1) | CN101910176A (es) |
| AR (1) | AR070071A1 (es) |
| AT (1) | ATE524468T1 (es) |
| AU (1) | AU2008351926A1 (es) |
| BR (1) | BRPI0821674A2 (es) |
| CA (1) | CA2710943A1 (es) |
| CL (1) | CL2008003926A1 (es) |
| CO (1) | CO6321243A2 (es) |
| EA (1) | EA201070816A1 (es) |
| FR (1) | FR2925900B1 (es) |
| IL (1) | IL206668A0 (es) |
| MA (1) | MA32060B1 (es) |
| MX (1) | MX2010007348A (es) |
| TW (1) | TW200942539A (es) |
| UY (1) | UY31586A1 (es) |
| WO (1) | WO2009106748A2 (es) |
| ZA (1) | ZA201004641B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2903108B1 (fr) * | 2006-07-03 | 2008-08-29 | Sanofi Aventis Sa | Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique. |
| FR2925906B1 (fr) * | 2008-01-02 | 2010-08-20 | Sanofi Aventis | COMPOSES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| FR2950344B1 (fr) | 2009-09-18 | 2011-11-25 | Sanofi Aventis | Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2638161B1 (fr) * | 1988-10-24 | 1991-01-11 | Centre Nat Rech Scient | Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| US20050171172A1 (en) * | 2003-11-13 | 2005-08-04 | Ambit Biosciences Corporation | Amide derivatives as PDGFR modulators |
| CA2589773A1 (en) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
| FR2903108B1 (fr) * | 2006-07-03 | 2008-08-29 | Sanofi Aventis Sa | Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique. |
| FR2903107B1 (fr) * | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2925906B1 (fr) * | 2008-01-02 | 2010-08-20 | Sanofi Aventis | COMPOSES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
-
2008
- 2008-01-02 FR FR0800002A patent/FR2925900B1/fr not_active Expired - Fee Related
- 2008-12-30 AR ARP080105776A patent/AR070071A1/es unknown
- 2008-12-30 CL CL2008003926A patent/CL2008003926A1/es unknown
- 2008-12-30 UY UY31586A patent/UY31586A1/es not_active Application Discontinuation
- 2008-12-31 JP JP2010541082A patent/JP2011508758A/ja not_active Withdrawn
- 2008-12-31 CA CA2710943A patent/CA2710943A1/fr not_active Abandoned
- 2008-12-31 CN CN200880123840XA patent/CN101910176A/zh active Pending
- 2008-12-31 MX MX2010007348A patent/MX2010007348A/es active IP Right Grant
- 2008-12-31 TW TW097151693A patent/TW200942539A/zh unknown
- 2008-12-31 EP EP08872826A patent/EP2225241B1/fr active Active
- 2008-12-31 AT AT08872826T patent/ATE524468T1/de not_active IP Right Cessation
- 2008-12-31 EA EA201070816A patent/EA201070816A1/ru unknown
- 2008-12-31 WO PCT/FR2008/001833 patent/WO2009106748A2/fr not_active Ceased
- 2008-12-31 KR KR1020107014641A patent/KR20100099245A/ko not_active Withdrawn
- 2008-12-31 AU AU2008351926A patent/AU2008351926A1/en not_active Abandoned
- 2008-12-31 BR BRPI0821674-6A patent/BRPI0821674A2/pt not_active IP Right Cessation
-
2010
- 2010-06-28 IL IL206668A patent/IL206668A0/en unknown
- 2010-07-01 US US12/828,369 patent/US20100317685A1/en not_active Abandoned
- 2010-07-01 ZA ZA2010/04641A patent/ZA201004641B/en unknown
- 2010-07-02 CO CO10080881A patent/CO6321243A2/es not_active Application Discontinuation
- 2010-08-02 MA MA33058A patent/MA32060B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY31586A1 (es) | 2009-08-03 |
| BRPI0821674A2 (pt) | 2015-06-16 |
| AU2008351926A1 (en) | 2009-09-03 |
| MA32060B1 (fr) | 2011-02-01 |
| FR2925900B1 (fr) | 2011-03-04 |
| WO2009106748A3 (fr) | 2009-12-30 |
| CN101910176A (zh) | 2010-12-08 |
| EA201070816A1 (ru) | 2010-12-30 |
| KR20100099245A (ko) | 2010-09-10 |
| CL2008003926A1 (es) | 2010-02-12 |
| WO2009106748A2 (fr) | 2009-09-03 |
| TW200942539A (en) | 2009-10-16 |
| MX2010007348A (es) | 2010-08-18 |
| US20100317685A1 (en) | 2010-12-16 |
| IL206668A0 (en) | 2010-12-30 |
| EP2225241B1 (fr) | 2011-09-14 |
| JP2011508758A (ja) | 2011-03-17 |
| FR2925900A1 (fr) | 2009-07-03 |
| CO6321243A2 (es) | 2011-09-20 |
| CA2710943A1 (fr) | 2009-09-03 |
| ATE524468T1 (de) | 2011-09-15 |
| ZA201004641B (en) | 2011-09-28 |
| EP2225241A2 (fr) | 2010-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| PE20091321A1 (es) | Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion en terapeutica | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| UY30183A1 (es) | Derivados de quinolina | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| DK2361609T3 (da) | Formulering af småmolekylære lægemidler med forsinket frigivelse | |
| PE20081549A1 (es) | Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamida y su preparacion | |
| AR068057A1 (es) | Esteres de 1-fenil-2-(3,5-dicloro)-piridina, metodo de preparacion de los mismos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades del tracto respiratorio. | |
| AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| PE20090694A1 (es) | Compuestos moduladores de sirtuinas | |
| PE20130339A1 (es) | Compuestos heterociclicos y sus usos | |
| PE20090724A1 (es) | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso | |
| AR078201A1 (es) | Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos | |
| AR063643A1 (es) | Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas | |
| ECSP088763A (es) | Nuevas combinaciones terapéuticas para el tratamiento de la depresión | |
| AR077892A1 (es) | Quinolinas antagonistas de la hepcidina | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| PE20091092A1 (es) | Compuestos heterociclicos como inhibidores de la via hedgehog | |
| UY29609A1 (es) | Derivados de benzamidina y usos relacionados de los mismos | |
| MX391445B (es) | Formas cristalinas de 3-(imidazol[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. | |
| NI200900042A (es) | Nuevo derivados de dismetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| PE20091436A1 (es) | Derivados de sulfonamidas sustituidas como moduladores b1r |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |